Literature DB >> 1410191

Fluvoxamine treatment for chronic PTSD: a pilot study.

M De Boer1, W Op den Velde, P J Falger, J E Hovens, J H De Groen, H Van Duijn.   

Abstract

A group of 24 Dutch World War II Resistance veterans with a documented traumatic war history and a (partially) positive diagnosis of current posttraumatic stress disorder (PTSD) was studied. This special group of war victims is characterised by chronicity, suffering from intractable posttraumatic complaints for decades. They were treated with fluvoxamine (Fevarin), a selective serotonin reuptake inhibitor with antidepressive and anxiolytic properties. The study was designed as an open-ended, outpatient pilot study, with a treatment period of 12 weeks. Results of clinical examination, and questionnaires investigating PTSD, depression, sleeping problems, anxiety, and vital exhaustion indicate that a significant number of the subjects improved with respect to their PTSD symptomatology, and their symptoms of anxiety and vital exhaustion. However, at the end of the study, quantitative improvement was modest. The results indicate that treatment with fluvoxamine may offer alleviation of chronic PTSD symptoms, in particular insomnia, nightmares, anxiety, intrusive recollections, guilt feelings and tiredness.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1410191     DOI: 10.1159/000288593

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  17 in total

1.  Best practice guide for the treatment of nightmare disorder in adults.

Authors:  R Nisha Aurora; Rochelle S Zak; Sanford H Auerbach; Kenneth R Casey; Susmita Chowdhuri; Anoop Karippot; Rama K Maganti; Kannan Ramar; David A Kristo; Sabin R Bista; Carin I Lamm; Timothy I Morgenthaler
Journal:  J Clin Sleep Med       Date:  2010-08-15       Impact factor: 4.062

2.  Position Paper for the Treatment of Nightmare Disorder in Adults: An American Academy of Sleep Medicine Position Paper.

Authors:  Timothy I Morgenthaler; Sanford Auerbach; Kenneth R Casey; David Kristo; Rama Maganti; Kannan Ramar; Rochelle Zak; Rebecca Kartje
Journal:  J Clin Sleep Med       Date:  2018-06-15       Impact factor: 4.062

Review 3.  Post-traumatic stress disorder and serotonin: new directions for research and treatment.

Authors:  L L Davis; A Suris; M T Lambert; C Heimberg; F Petty
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

Review 4.  Management of Post-Traumatic Nightmares: a Review of Pharmacologic and Nonpharmacologic Treatments Since 2013.

Authors:  Scott H Waltman; David Shearer; Bret A Moore
Journal:  Curr Psychiatry Rep       Date:  2018-10-11       Impact factor: 5.285

Review 5.  Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management.

Authors:  Michael J Maher; Simon A Rego; Gregory M Asnis
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  Anxiety disorders in older adults.

Authors:  J A Sable; D V Jeste
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

Review 7.  Anxiety disorders in late life.

Authors:  A J Flint
Journal:  Can Fam Physician       Date:  1999-11       Impact factor: 3.275

Review 8.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 9.  SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations.

Authors:  Gregory M Asnis; Shari R Kohn; Margaret Henderson; Nicole L Brown
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Psychopharmacotherapy of posttraumatic stress disorder.

Authors:  Dragica Kozaric-Kovacic
Journal:  Croat Med J       Date:  2008-08       Impact factor: 1.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.